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Efficacy of cupping therapy in 
patients with the fibromyalgia 
syndrome-a randomised placebo 
controlled trial
Romy Lauche1,2, Julia Spitzer1,*, Barbara Schwahn1,*, Thomas Ostermann3, 
Kathrin Bernardy4, Holger Cramer1,2, Gustav Dobos1 & Jost Langhorst1
This study aimed to test the efficacy of cupping therapy to improve symptoms and quality of life 
in patients diagnosed with the fibromyalgia syndrome. Participants were randomly assigned to 
cupping therapy, sham or usual care. Cupping was administered five times at twice weekly intervals 
on the upper and lower back. The primary outcome measure was pain intensity at day 18. Secondary 
outcomes included functional disability, quality of life, fatigue and sleep quality as well as pressure pain 
sensitivity, satisfaction and safety at day 18 and 6 months. Altogether 141 patients were included in this 
study (139 females, 55.8 ± 9.1 years). After 18 days patients reported significant less pain after cupping 
compared to usual care (difference −12.4; 95% CI: −18.9; −5.9, p < 0.001) but not compared to sham 
(difference −3.0; 95% CI: −9.9, 3.9, p = 0.396). Further effects were found for quality of life compared 
to usual care. Patients were mildly satisfied with cupping and sham cupping; and only minor side effects 
were observed. Despite cupping therapy being more effective than usual care to improve pain intensity 
and quality of life, effects of cupping therapy were small and comparable to those of a sham treatment, 
and as such cupping cannot be recommended for fibromyalgia at the current time.
The fibromyalgia syndrome is a condition characterised by chronic widespread pain in combination with fatigue, 
cognitive disturbances, sleep disorders and pronounced somatic and/or psychological distress1,2. Between 2.9 and 
3.8% of the general population in Europe suffer from fibromyalgia1,3, the majority of them being women2. Only 
a few complementary therapies have been recommended in the treatment guidelines4, however cupping therapy 
has not been included due to the lack of evidence5,6.
Cupping therapy is an ancient medical therapy, and the common denominator in all cupping variations is the 
application of suction to the skin7,8. Several techniques from traditional cupping - where skin incisions are made 
to allow blood and other body fluids to escape - to dry cupping and cupping massage -where no such incisions 
are made – are available8. According to common theories the effects of cupping may include increased microcir-
culation, tissue detoxification and a subsequent relief of painful muscle tension9,10. Favourable effects of cupping 
therapy have been found in patients with chronic pain conditions11, for example neck pain12–15, low back pain16–19 
or migraine20, however for fibromyalgia only evidence from an uncontrolled Chinese study is available showing 
that two weeks of daily cupping lead to a substantial decrease in pain intensity. Since patients with the fibromy-
algia syndrome have reported a high prevalence for the use of complementary and alternative therapies21 more 
studies are needed to establish a robust evidence-base for the efficacy of such interventions.
This study aimed to investigate the efficacy of cupping therapy compared to usual care and a sham procedure 
to improve symptoms and quality of life in patients diagnosed with the fibromyalgia syndrome.
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Methods
Ethical approval and trial registration. The trial was conducted between October 2012 and February 
2015 in the Department of Complementary and Integrative Medicine in Essen, Germany. The study was 
approved by the ethics committee of the University Hospital Essen (approval number: 12-5056-BO) and regis-
tered at ClinicalTrials.gov (registry number: NCT01635634, date of registration 03 July 2012), prior to patient 
recruitment. The study was conducted according to common standard guidelines for clinical trials (Declaration 
of Helsinki, and the International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use and Good Clinical Practice (ICH-GCP) revised version, Somerset West, 
Republic of South Africa, 1996).
Design. This was a randomised sham-controlled three-armed parallel group trial. The intervention group 
received five sessions of dry cupping, whereas the control groups received either five sessions of sham cupping, or 
usual care. Each group received the allocated intervention within 18 days; measurements were conducted at day 
0, day 18 and after 6 months. After the measurements at day 18 usual care group patients received the cupping 
treatment.
Patients. Patients were recruited via newspaper advertisements, with medical students screening interested 
people by phone to assess their eligibility. Patients who met the inclusion criteria were invited for assessment 
where they were provided with detailed written information about the study; and their written informed con-
sent was obtained. The study physician checked patients’ medical histories, examined their physical health, and 
checked patients’ medical records. If patients met the inclusion criteria, and did not meet any exclusion criteria, 
they were included.
Trial participants were required to be between 18 and 75 years of age, and to suffer from the fibromyalgia syn-
drome diagnosed by a specialist. The 2010 American College of Rheumatology diagnostic criteria22 were checked 
to confirm diagnosis in all patients. Patients further had to report at least moderate pain of 45 mm or higher on a 
visual analogue scale (VAS)23, with 100 mm described as “worst pain imaginable”.
The trial exclusion criteria included pain due to inflammatory rheumatic disorder, any major psychiatric dis-
order, severe depression or substance abuse, any severe comorbidity such as cancer or neurological disorders, 
recently initiated or modified drug treatment, prior injections or acupuncture (within the past 3 months or during 
the trial), treatment with opioids or steroidal pain medication. Medications with non-steroidal anti-inflammatory 
drugs or antidepressants were admitted if the dosage was kept constant during the trial. Finally pregnant or lac-
tating women or patients taking part in other clinical trials were excluded.
Randomization and allocation procedure. Patients were allocated to one of three groups in sequential 
order adopting a computer-generated (Random Allocation Software, version 1.0.0) stratified block randomiza-
tion with randomly varying block sizes. The following stratum was applied: Patients taking antidepressants vs. 
those without. The trial coordinator who was not involved in patients’ outcome assessments prepared sealed 
opaque envelopes. Envelopes were labelled according to the study participant’s identification number and after 
inclusion, the envelopes were opened in ascending order by the study physician and the patients were allocated 
to the respective intervention.
Blinding. Patients were blinded twice: 1) to the fact that a sham procedure was used, instead they were told 
that two different cupping techniques would be compared against each other, i.e. traditional cupping vs. mod-
ern gentle cupping; 2) to whether they have been allocated to the real or sham cupping. Success of blinding was 
checked at day 18. Outcome assessors were blinded to the patients’ group allocation (all groups) at outcome 
assessment.
Intervention. After the baseline measurement and randomization patients received the allocated treatment.
Cupping therapy. Patients in that group received five cupping treatments, two treatments per week. Cupping 
was performed on the patients’ upper and lower back in a semi-standardised manner. Four to eight 50–100 mm 
diameter acrylic glass cups were placed on the skin, and air was partially evacuated from the cups by means of a 
mechanical device (Pneumatron® 200S, Pneumed GmbH, Idar-Oberstein, Germany). The negative pressure was 
adjusted to a comfortable level, and cups were fixed by means of elastic tapes. After 10 to 15 minutes cups were 
removed. The cups were placed on predefined locations such as the trapezius, the levator, the latissimus dorsi, or 
the gluteus maximus muscles; as well as individually according to the patient’s physical examination. One treat-
ment session lasted about 30 minutes in total.
Sham Cupping Therapy. The same procedures were applied, however the cupping glasses had been prepared 
with small holes of < 1 mm diameter to release the negative pressure within seconds. The cups were also fixed by 
means of elastic tapes. The sham treatment followed the procedure described earlier24. Patients in both cupping 
groups were told that they might feel suction initially, but this sensation would usually disappear after a few sec-
onds, because receptors in the skin would adapt to the stretch of the skin. Patients in both cupping groups were 
also advised that they could continue their usual activities and therapies, but not to initiate any new therapeutic 
regimen for symptom management.
Usual care group. Patients in this group were advised to continue their usual activities and therapies, but not 
to initiate any new therapeutic regimen for symptom management. After baseline measurement they were asked 
to return at day 18 for their final examination, after which they received the cupping therapy.
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Assessment. Patients’ Expectation. At the assessment visit all patients rated their expectations that tradi-
tional cupping or gentle cupping would improve their pain on a 100 mm VAS with 100 mm indicating ‘highest 
possible expectation’.
Compliance. The number of received cupping sessions for each patient was documented.
Questionnaires. Current pain intensity was measured using a 0–100 mm visual analogue scale from the German 
Pain Questionnaire25,26 with 0 mm indicating ‘no pain at all’ and 100 mm indicating ‘worst pain imaginable’.
The fibromyalgia impact questionnaire (FIQ)27,28 was used to determine health status and functioning of fibro-
myalgia patients. The FIQ is composed of 20 items, and patients can score between 0 and 100 points with higher 
scores indicating higher impairments. Scores above 70 usually indicate severe affliction.
Health-related quality of life was assessed using the Short Form 36 Health Survey Questionnaire (SF-36)29. 
This widely used comprehensive 36-item questionnaire yields an 8-scale health profile as well as two component 
summaries of physical and mental health-related quality of life.
The Multidimensional Fatigue Inventory (MFI-20) - a 20-item, multi-dimensional, self-report instrument 
– was used to measure severity of fatigue30,31. The instrument covers 5 dimensions; and shows good internal con-
sistency and reliability. Possible scores for each scale range from 4–20 with higher scores indicating more severe 
fatigue.
Sleep disturbance was assessed on the Pittsburgh Sleep Quality Inventory (PSQI)32. Results of the PSQI are 
presented as seven subscales (max. 3 points each) and one total score (max. 21 points), with higher values indi-
cating more severe sleep disturbances32.
All patients used a log to record the intensity on a 100 mm visual analogue scale, whether they took analgesics 
or received other treatments. For analgesics the defined daily doses were calculated33; for concomitant treatments 
the relative frequencies of days on which they received any intervention was analysed. In order to condense data 
and compensate for different periods of time between treatments, pain, medication and concomitant treatments 
between two treatments or between the last session and the measurement at day 18 were averaged.
Pressure pain threshold. Patients’ pressure pain thresholds (PPT) were measured using a digital algometer 
(Somedic AB, Hörby, Sweden) with a 1 cm2 probe. Pressure was applied in increments of 40 kPa/s until patients 
indicated a perception of pain in addition to pressure. They were measured unilaterally over the patient’s right 
thenar eminence for demonstration34; bilaterally at three predefined sites: over the levator scapulae muscle 
(medial to insertion on angulus superior scapulae), the descending part of the trapezius muscle (midway between 
C7 and the acromion process) and the gluteus maximus muscle (at the upper, outer quadrants of buttocks in ante-
rior fold of muscle); as well as unilaterally at the site of maximal pain. The averages of three measurements each 
were log-transformed (lg) and analysed35,36.
Success of blinding. To determine whether blinding was successful patients were asked to indicate which form of 
cupping therapy they had received in their opinion.
Satisfaction with interventions. After 18 days patients were asked to judge how beneficial the respective treat-
ment was on a 100 mm visual analogue scale with 100 mm indicating highest possible benefit, whether they would 
utilise this intervention in the future and whether they would recommend it to family or friends on a yes/no basis.
Safety. All adverse events were recorded. Patients experiencing such events were asked to see the study physi-
cian to assess their import and initiate any necessary response.
Primary and secondary outcome measures. The primary outcome measure was pain intensity at day 18 as meas-
ured by the visual analogue scale (VAS). Secondary outcome measures included pain (VAS), physical function 
(FIQ), quality of life (SF-36), fatigue (MFI), sleep quality (PSQI) at day 18 and 6 months; pressure pain sensitivity 
(PPT) at day 18; and pain intensity (VAS), pain medication and concomitant treatments from the daily log, com-
pliance, satisfaction, success of blinding and safety.
Sample size calculation. No data were available for a priori sample size calculation for cupping therapy in 
patients with fibromyalgia. Instead data from a reanalysis on cupping therapy were used37. Those data were gath-
ered in a comparable setting with chronic neck pain patients. A minimal clinically important difference according 
to Lauche et al.37 was 8 mm VAS on the primary outcome with a standard deviation of 13 mm. Given the effect 
size of Cohen’s d = 0.615, and a two-sided 5% level t-test with a statistical power of 1-β = 80%, 43 patients would 
be needed to detect this group difference. We planned to include 141 patients in this trial (n = 47 per group); 
recognizing a potential loss of analytical power due to patient withdrawal from 10%.
Statistical analysis. All analyses were based on the intention to treat population, i.e. each patient providing 
baseline data was included in the final analysis. Missing data were substituted using the arithmetical average of 50 
complete data sets created by the Markov-Chain-Monte-Carlo multiple imputation procedure in SPSS. Pain and 
medication diary were analysed using the per-protocol population only.
The primary outcome was analysed using the univariate analysis of covariance (ANCOVA) which modelled 
the post-treatment outcome as a function of treatment group (classified factor), and the respective baseline value 
(linear covariate). A stepwise analysis was conducted; starting with the comparison cupping therapy vs. usual 
care; followed by cupping therapy vs. sham cupping, each with a p-value of 0.05 indicating significant differences. 
Within this model the treatment effect was estimated, accompanied with a 95% confidence interval. The p-value 
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was based on a two-sided t-test within this statistical model. All other outcomes were defined as secondary out-
comes and were analysed exploratively only using comparable models, without reporting p-values. This way, no 
alpha level adjustment was necessary to maintain the overall type I error rate of 5%38,39.
For secondary outcomes the same statistical models were used. The frequencies of responders, i.e. patients 
experiencing at least 30% or 50% pain reduction, were compared between groups using χ 2 tests. Results from 
the daily log were analysed using a repeated measurement analysis of variance (ANOVA) with group as the 
between-subject-factor and pain outcomes at the different time points as the dependent variables. Medication 
and treatment logs were analysed with the same model. In case of significant main or interaction effects, post hoc 
tests (ANOVA, student’s t-tests) were conducted. All analyses were performed using the Statistical Package for 
Social Sciences software (IBM SPSS Statistics for Windows, release 22.0. Armonk, NY: IBM Corp.).
Results
Patients. From 362 patients initially screened by telephone, 150 patients were seen by the study physician, 
of whom 141 were enrolled. The most common reasons for excluding patients were violations of the inclusion 
criteria, or lost interest in the study. Of the 141 patients finally enrolled, all were randomised and allocated to their 
intervention. During the intervention seven patients each were lost to follow-up in cupping therapy and sham 
cupping, due to adverse events, private or unknown reasons. In the usual care group five patients were lost for 
similar reasons. A high proportion of patients withdrew from the study during the long-term follow up (see Fig. 1 
for CONSORT flowchart).
Baseline characteristics. Patients were 55.8 ± 9.1 years on average; and 139 women and two men were 
included, see Table 1. The majority of patients had an education below high school level, and a third each was 
Figure 1. CONSORT Flowchart of patient recruitment and study flow. 
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unemployed or retired. About 40% of patients in each group were currently taking antidepressants. Patients had 
received many therapies in the past, mainly medication or physiotherapy. Patients reported that their pain had 
been present for 12 years on average.
Patients’ Expectation. There were no differences between the patients’ expectations towards the cupping inter-
ventions (‘traditional’ cupping: 68.1 ± 18.9 mm VAS; ‘gentle’ cupping: 64.7 ± 23.3 mm; p = 0.435).
Compliance. Altogether 38 out of 47 patients received five cupping treatments (80.9%), and 38 out of 48 received 
five sham treatments (79.2%).
Outcome measures. Primary outcome measure. Analysis of pain intensity revealed a significant group 
difference between cupping therapy and usual care (difference − 12.4, 95% CI: − 18.9, − 5.9, p < 0.001) at day 18 
in favour of cupping, see Table 2. No group difference was found between cupping therapy and sham cupping 
(difference − 3.0, 95% CI: − 9.9, 3.9, p = 0.396), see Table 2.
After 18 days 12 patients in cupping therapy (25.5%) and nine patients in sham cupping (18.8%) reported a 
30% pain reduction while only one patient in usual care did (2.2%) (p = 0.006). At least 50% pain reduction was 
reported by four (8.5%), five (10.4%) and zero (0.0%) patients in cupping therapy, sham cupping and usual care 
respectively (p = 0.091).
Secondary outcome measures. No difference between cupping therapy and usual care was found for physical 
function (FIQ) or sleep quality (PSQI). For quality of life, group differences in favour of cupping therapy were 
found for the scales bodily pain (difference 4.7, 95% CI: 0.9, 8.6), vitality (difference 6.3, 95% CI: 0.9, 11.7), social 
role functioning (difference 7.1, 95% CI: 0.1, 14.1) and mental health (difference 4.5, 95% CI: 0.0, 8.9), as well 
as for the mental component summary (difference 3.4, 95% CI: 0.8, 5.9), see Table 2. For fatigue only the scale 
reduced motivation revealed group differences (difference − 1.2, 95% CI: − 2.1, − 0.2) in favour of cupping ther-
apy. For pressure pain sensitivity differences were found for the left levator scapulae muscle, the left and right 
gluteus maximus muscle and the site of maximal pain (all p < 0.01), see Table 3.
Item
Cupping 





Age in years, Mean ± SD 54.35 ± 10.6 56.3 ± 8.7 56.8 ± 7.7
Gender n (female)/n (male) 46/1 47/1 46/0
BMI in kg/m2, Mean ± SD 29.4 ± 7.3 27.2 ± 4.7 28.2 ± 5.4
Marital status, n (%)
 Single 5 (10.6) 2 (4.2) 4 (8.7)
 In relationship, married 31 (66.0) 32 (66.7) 30 (65.2)
 Separated, divorced, widowed 11 (23.4) 14 (29.2) 12 (26.1)
Education, n (%)
 < High school 35 (74.5) 33 (68.8) 32 (69.6)
 High school 10 (21.3) 8 (16.7) 6 (13.0)
 University degree 2 (4.3) 7 (14.6) 8 (17.4)
Employment, n (%)
 Unemployed 14 (29.8) 12 (25.0) 4 (8.7)
 Employed 16 (34.0) 19 (39.6) 21 (45.7)
 Retired (health related) 17 (11) 17 (9) 21 (16)
  Duration of pain in years, 
Mean ± SD 11.6 ± 9.2 11.2 ± 8.9 13.0 ± 8.4
Previous therapies, received, n (%)
 Medication 38 (80.9) 42 (87.5) 38 (82.6)
 Physiotherapy 36 (76.6) 38 (79.2) 35 (76.1)
 Chiropractic 13 (27.7) 14 (29.2) 14 (30.4)
 Psychotherapy 22 (46.8) 29 (60.4) 20 (43.5)
 Acupuncture 29 (61.7) 33 (68.8) 32 (69.6)
 Relaxation 26 (55.3) 25 (52.1) 19 (41.3)
 Rehabilitation center 27 (57.5) 26 (54.2) 25 (54.4)
Current Medication, n (%)
 Antidepressants 18 (38.3) 18 (37.5) 17 (37.0)
Expectation (Mean ± SD)
 Traditional Cupping, mm VAS 68.1 ± 18.9 67.5 ± 20.8 73.4 ± 19.2
 “Gentle Cupping” (Sham), mm VAS 70.6 ± 21.4 64.7 ± 23.3 71.4 ± 21.8
Table 1.  Baseline characteristics of trial patients according to study arms: Cupping therapy, sham cupping 
and usual care.
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Compared to sham cupping no differences were found for any outcomes except for one on the scale bodily 
pain of the SF-36 at day 18 (difference 5.1, 95% CI: 0.5, 9.6), see Table 2.
Success of blinding. Success of blinding was tested using χ 2 test. Altogether 32 out of 39 (82.1%) of the patients 
in cupping therapy, and 30 out of 41 (73.2%) of the patients in sham cupping correctly identified their respective 
group allocation indicating lack of success of blinding (p < 0.0001).
Daily log. A small but consistent decline in pain intensity was found in cupping and sham cupping, but not in 
usual care (Fig. 2a). Repeated measures ANOVA revealed a time × group interaction. Post hoc analysis showed a 
decline in pain intensity only within the cupping group. Group differences between cupping and usual care; and 
sham cupping and usual care were found only after the fifth cupping session. Analgesic medication (Fig. 2b) and 
concomitant therapies (Fig. 2c) decreased during the study period with no group differences. Altogether the rate 
of analgesic consumption or concomitant therapies was low in general.
Satisfaction with interventions. Patients were mildly satisfied with both interventions at day 18 (average ben-
efit on a 100 mm visual analogue scale: cupping therapy: 56.9 ± 28.6 mm; sham cupping: 39.7 ± 27.2 mm). 
Furthermore 25 out of 39 (64.1%) would consider using cupping therapy again, so did 22 in sham cupping 
(57.9%). And 32 out of 39 (82.1%) and 34 out of 40 (85.0%) would recommend cupping therapy and sham cup-
ping to family and friends respectively.
Safety. The following non-serious adverse events were recorded in the cupping group: two patients reported 
severely increased pain after cupping, one patient had an accident with bruised rips and one patient had the flu. 
All events resolved without intervention. A fifth patient suffered from acute torticollis which radiated into the 
arm but was resolved without treatment within days. In sham cupping two serious adverse events were reported: 
one patient with a torn meniscus and one patient with persistent pain after spinal operation. Both patients had 
consulted a specialist on their own. A third patient in that group had the flu. No patient in the usual care group 
reported adverse events.
Discussion
This trial included 141 mainly female patients with the fibromyalgia syndrome, and found that five cupping treat-
ments were more effective than usual care to improve pain and mental quality of life. Cupping however was not 
superior to sham cupping. Patients were able to distinguish the two types of cupping, and were mildly satisfied 
Cupping Usual Care Estimated 
group difference 
between Cupping 









Cupping and Sham 
at 6 MonthsBaseline Day 18 6 Months Baseline Day 18 Baseline Day 18 6 Months
Pain intensity 
(mm VAS) 55.5 ± 21.0 51.1 ± 20.9 58.5 ± 17.5 54.5 ± 20.9 62.9 ± 18.7
− 12.4 (− 18.9;  
− 5.9) p < 0.001 58.9 ± 22.3 56.4 ± 23.91 60.7 ± 17.8
− 3.0 (− 9.9; 3.9) 
p = 0.396 − 1.2 (− 8.0;5.5)
Function (FIQ)
 FIQ total score 55.7 ± 12.8 53.2 ± 16.8 56.9 ± 14.9 61.4 ± 14.1 61.5 ± 15.4 − 2.5 (− 6.0; 1.1) 61.8 ± 11.8 58.3 ± 13.4 61.2 ± 14.1 0.5 (− 3.7; 4.8) 0.4 (− 4.2; 5.0)
Quality of life (SF-36)
  Physical 
component 
summary
31.6 ± 7.3 34.0 ± 8.6 34.3 ± 8.4 31.2 ± 7.6 32.9 ± 7.3 0.8 (− 1.3; 2.9) 31.7 ± 7.4 32.4 ± 8.5 32.7 ± 8.8 1.8 (− 0.6; 4.1) 1.7 (− 0.9; 4.3)
  Mental 
component 
summary
41.1 ± 12.1 43.9 ± 11.8 39.9 ± 12.4 40.1 ± 13.0 39.6 ± 13.8 3.4 (0.8; 5.9) 37.6 ± 11.1 40.2 ± 11.2 37.2 ± 11.6 0.9 (− 2.2; 3.9) − 0.1 (− 3.4; 3.3)
  Physical 
functioning 50.3 ± 24.5 53.4 ± 22.2 55.7 ± 20.2 48.9 ± 21.4 48.2 ± 19.0 4.2 (− 0.7; 9.1) 48.1 ± 20.8 49.1 ± 20.0 51.2 ± 20.4 2.7 (− 2.5; 7.8) 3.2 (− 3.1; 9.4)
  Physical role 
functioning 23.8 ± 27.3 39.5 ± 36.3 35.5 ± 29.4 19.6 ± 29.8 30.2 ± 37.0 5.8 (− 5.8; 17.5) 11.5 ± 22.5 23.3 ± 30.6 25.1 ± 25.6 7.0 (− 4.8; 18.8) 3.2 (− 6.7; 13.1)
 Bodily Pain 29.1 ± 13.9 38.5 ± 16.1 33.5 ± 14.0 26.5 ± 14.1 31.5 ± 14.1 4.7 (0.9; 8.6) 29.0 ± 9.9 33.4 ± 14.3 30.8 ± 14.4 5.1 (0.5; 9.6) 2.7 (− 2.6; 7.9)
  General 
Health 
Perception
39.2 ± 16.1 42.4 ± 18.6 42.2 ± 20.2 41.5 ± 18.0 43.9 ± 16.6 0.4 (− 3.9; 4.7) 42.6 ± 14.6 42.2 ± 16.5 39.9 ± 15.5 2.9 (− 2.2; 8.0) 5.1 (− 0.1; 10.4)
 Vitality 33.5 ± 18.6 38.9 ± 19.9 34.6 ± 19.2 31.3 ± 17.8 30.7 ± 21.2 6.3 (0.9; 11.7) 31.2 ± 16.6 33.2 ± 14.9 31.0 ± 14.0 4.1 (− 1.4; 9.7) 2.2 (3.3; 7.8)
  Social role 
functioning 55.3 ± 27.6 60.6 ± 26.3 56.7 ± 24.4 52.6 ± 27.9 51.5 ± 28.3 7.1 (0.1; 14.1) 48.9 ± 19.1 54.6 ± 23.0 52.2 ± 23.4 0.7 (− 6.7; 8.2) − 0.9 (− 7.8; 5.9)
  Emotional role 
functioning 43.2 ± 42.8 56.0 ± 42.7 45.0 ± 33.6 48.6 ± 45.9 48.5 ± 41.9 10.8 (− 2.4; 24.1) 31.9 ± 39.5 45.0 ± 41.2 39.7 ± 34.3 2.8 (− 9.3; 14.9) − 0.1 (− 11.6;11.5)
 Mental health 56.3 ± 18.1 60.5 ± 19.4 55.1 ± 19.7 50.6 ± 19.7 50.4 ± 23.4 4.5 (0.0; 8.9) 50.3 ± 16.7 53.2 ± 18.0 48.9 ± 18.1 2.4 (− 2.5; 7.3) 1.2 (− 3.9; 6.2)
Table 2.  Results of statistical analysis for pain and quality of life between trial groups at day 18 and 6 
months. Estimated group differences from the ANCOVA and 95% Confidence Intervals (CI) are presented.
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with either intervention. Adverse events related to cupping therapy mainly included increased pain, no serious 
adverse events related to the intervention were observed.
Scientific evidence. Only one trial could be located during literature search40. Cao and colleagues inves-
tigated 30 patients. Cupping was performed daily for 15 days with bamboo cups that had been boiled in herbal 
decoction before the application. The authors found a pain decrease by 48% on average; and the effect was sus-
tained at two weeks follow-up. In our current study cupping was not nearly as effective, for a number of possible 
reasons. Patients may not have been comparable between the studies as indicated by different pain levels and 
medication use. Cupping in the previous trial was also performed more frequently, and there might have been 
effects due to the herbal decoction. Patients in the trial were also diagnosed with the 1990 criteria of the American 
College of Rheumatology2, while diagnosis in our current trial was confirmed on the basis 2010 ACR criteria 
without the presence of tender point counts.
Cupping was also less effective than for chronic non-specific neck pain12,13 where a 30–50% pain reduction 
was found after 5 cupping treatments. However aetiology of chronic neck pain and fibromyalgia are – despite 
large knowledge gaps in the understanding of fibromyalgia still – rather different, with proposed abnormalities in 
central and peripheral pain processing in fibromyalgia patients41–45 as well as a high comorbidity of psychological 
disorders46,47.
Interestingly the present trial found no difference between cupping and sham cupping. This is even more 
surprising since the majority of patients were able to determine their respective group allocation correctly. This is 
in contrast to findings from Lee et al.24 who developed the sham cupping procedure. Their participants had been 
informed that half of them would receive sham cupping; however most participants were unsure what cupping 
they had received; and only a few participants uncovered their allocation. In our present trial the patients’ success 
to uncover the group allocation is even more remarkable because the patients were cupping naïve, i.e. they had no 
former experiences with cupping therapy.
One would think that once the patients uncover their group assignment the sham intervention would be 
inefficacious. But it was never revealed to the participants that a sham intervention was used, it was introduced 
Cupping Usual Care Estimated group 
difference between 
Cupping and Usual 
Care at Day 18
Sham Estimated group 
difference between 
Cupping and 
Sham at Day 18
Estimated group 
difference between 
Cupping and Sham 
at 6 monthsBaseline Day 18 6 months Baseline Day 18 Baseline Day 18 6 months
Pain perception (SBL)
  Affective pain 
perception 4.2 ± 3.7 4.6 ± 3.7 4.8 ± 3.3 5.0 ± 3.4 5.3 ± 3.2 0.1 (− 0.9; 1.2) 4.3 ± 3.8 4.1 ± 3.3 4.9 ± 2.8 0.6 (− 0.6; 1.7) − 0.0 (1.0; − 1.0)
  Sensory pain 
perception 11.6 ± 4.4 11.8 ± 4.4 12.5 ± 4.2 9.9 ± 5.8 11.3 ± 5.2 − 0.6 (− 2.2; 1.0) 11.6 ± 6.0 12.0 ± 5.2 13.1 ± 5.4 0.2 (− 1.7; 1.2) − 0.5 (− 2.3; 1.3)
Fatigue (MFI)
 General fatigue 15.2 ± 3.5 14.9 ± 3.7 14.7 ± 3.1 16.0 ± 3.3 15.9 ± 3.3 − 0.3 (− 1.3; 0.6) 15.6 ± 3.1 15.1 ± 2.9 15.3 ± 2.8 0.1 (− 1.0; 1.1) − 0.5 (− 1.6; 0.7)
 Physical fatigue 14.6 ± 2.7 14.4 ± 3.5 14.6 ± 2.6 15.2 ± 3.4 14.9 ± 3.4 − 0.1 (− 1.2; 1.0) 14.8 ± 2.5 14.1 ± 2.6 14.9 ± 3.0 0.3 (− 0.8; 1.3) − 0.2 (− 1.3; 0.9)
  Reduced motivation 11.2 ± 3.2 11.0 ± 3.1 11.6 ± 3.1 11.2 ± 3.8 12.2 ± 3.5 − 1.2 (− 2.1; − 0.2) 11.1 ± 3.2 11.3 ± 3.1 11.4 ± 2.9 − 0.3 (− 1.3; 0.8) 0.2 (− 1.0; 1.3)
 Reduced activity 12.4 ± 2.7 13.4 ± 3.5 13.5 ± 2.9 13.7 ± 3.6 14.0 ± 3.8 − 0.7 (− 2.3; 0.8) 13.2 ± 3.9 13.2 ± 2.8 14.1 ± 3.0 0.1 (− 1.2; 1.5) − 0.7 (− 1.9; 0.5)
 Mental fatigue 12.7 ± 3.9 12.6 ± 4.1 13.2 ± 3.5 13.2 ± 4.3 13.2 ± 3.8 − 0.3 (− 1.3; 0.7) 13.7 ± 2.7 13.4 ± 3.2 13.5 ± 3.3 − 0.0 (− 0.9; 0.9) 0.3 (− 0.8; 1.4)
Sleep (PSQI)
  Subjective sleep quality 1.7 ± 0.7 1.6 ± 0.7 1.7 ± 0.6 2.1 ± 0.7 1.9 ± 0.7 − 0.1 (− 0.3; 0.1) 1.9 ± 0.8 1.8 ± 0.8 1.9 ± 0.6 − 0.1 (− 0.3; 0.1) − 0.1 (− 0.3; 0.1)
 Sleep latency 1.7 ± 0.9 1.4 ± 1.0 1.6 ± 0.8 1.5 ± 1.0 1.7 ± 1.0 − 0.3 (− 0.7; 0.1) 1.8 ± 0.8 1.7 ± 0.8 1.7 ± 0.7 − 0.2 (− 0.6; 0.1) − 0.0 (0.3; − 0.3)
 Sleep duration 1.5 ± 1.2 1.6 ± 1.1 1.6 ± 0.9 1.5 ± 1.1 1.6 ± 1.0 0.0 (− 0.4; 0.4) 1.7 ± 1.1 1.8 ± 1.1 1.7 ± 0.9 − 0.2 (− 0.6; 0.3) − 0.1 (0.5; 0.2)
  Habitual sleep 
efficiency 1.3 ± 1.2 1.6 ± 1.2 1.6 ± 0.9 1.4 ± 1.2 1.5 ± 1.1 0.1 (− 0.4; 0.6) 1.5 ± 1.2 1.8 ± 1.1 1.7 ± 1.0 − 0.3 (− 0.7; 0.2) − 0.1 (− 0.5; 0.3)
 Sleep disturbances 1.8 ± 0.7 1.7 ± 0.6 1.8 ± 0.5 1.7 ± 0.7 2.0 ± 0.7 − 0.2 (− 0.5; − 0.0) 1.8 ± 0.6 1.9 ± 0.7 1.8 ± 0.6 − 0.2 (− 0.4; 0.1) − 0.0 (− 0.3; 0.2)
  Use of sleep medication 0.8 ± 1.2 0.7 ± 1.0 0.8 ± 0.9 0.5 ± 1.0 0.7 ± 1.0 − 0.2 (− 0.5; 0.1) 0.3 ± 0.8 0.6 ± 0.9 0.4 ± 0.5 − 0.2 (− 0.5; 0.1) 0.2 (− 0.1; 0.5)
 Daytime dysfunction 1.7 ± 0.8 1.7 ± 0.8 1.9 ± 0.7 1.8 ± 0.8 2.1 ± 0.8 − 0.3 (− 0.5; 0.0) 2.0 ± 0.7 1.8 ± 0.6 1.9 ± 0.6 0.1 (− 0.2; 0.3) 0.1 (− 0.2; 0.3)
 Global PSQI Score 10.3 ± 3.9 10.0 ± 4.0 10.8 ± 3.5 10.8 ± 3.8 11.2 ± 3.6 − 0.8 (− 1.7; 0.1) 10.8 ± 4.0 11.3 ± 4.3 10.9 ± 3.8 0.9 (− 0.1; 1.8) 0.3 (− 0.7; 1.2)
Pressure pain sensitivity
 Thenar 2.2 ± 0.2 2.1 ± 0.2 2.2 ± 0.2 2.1 ± 0.3 0.0 (0.0; 0.1) 2.1 ± 0.2 2.1 ± 0.2 − 0.0 (− 0.1; 0.0)
 Left Trapezius 2.0 ± 0.2 2.1 ± 0.2 2.1 ± 0.2 2.0 ± 0.2 0.1 (0.0; 0.1) 2.0 ± 0.2 2.0 ± 0.2 − 0.0 (0.0; 0.1)
 Right Trapezius 2.0 ± 0.3 2.0 ± 0.2 2.0 ± 0.2 2.0 ± 0.3 0.1 (0.0; 0.1) 2.0 ± 0.3 2.0 ± 0.2 − 0.0 (0.1; − 0.1)
 Left Levator 2.0 ± 0.2 2.1 ± 0.2 2.1 ± 0.3 2.0 ± 0.3 0.1 (0.0; 0.1) 2.0 ± 0.2 2.0 ± 0.2 − 0.0 (0.1; − 0.1)
 Right Levator 2.0 ± 0.3 2.1 ± 0.2 2.1 ± 0.3 2.0 ± 0.3 0.1 (0.0; 0.1) 2.0 ± 0.3 2.0 ± 0.2 − 0.0 (− 0.1; 0.0)
 Left Gluteus 2.0 ± 0.2 2.1 ± 0.2 2.1 ± 0.2 2.0 ± 0.3 0.1 (0.0; 0.1) 2.0 ± 0.2 2.1 ± 0.3 − 0.0 (0.1; − 0.1)
 Right Gluteus 2.0 ± 0.3 2.1 ± 0.2 2.1 ± 0.2 2.0 ± 0.3 0.1 (0.0; 0.2) 2.0 ± 0.3 2.1 ± 0.2 − 0.0 (0.1; − 0.1)
 Site of maximal pain 1.9 ± 0.2 2.0 ± 0.2 2.0 ± 0.2 1.9 ± 0.3 0.1 (0.0; 0.2) 1.9 ± 0.2 1.9 ± 0.3 − 0.0 (0.1; − 0.1)
Table 3.  Results of statistical analysis for secondary outcomes between trial groups at day 18 and 6 
months. Estimated group differences from the ANCOVA and 95% Confidence Intervals (CI) are presented.
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as ‘gentle’ cupping instead. This is in line with findings from a systematic review that found the magnitude of the 
placebo effect larger in trials with physical placebos and trials where the use of a placebo interventions were not 
disclosed48. The same review did not find significant effects of placebo interventions in pain conditions, however 
results of included trials showed inconsistent effects of placebo effects48. The gentle therapy was indeed preferred 
over the traditional cupping therapy and explicitly requested by trial participants. Therefore factors such as expec-
tations49, patient-practitioner-interaction and other positive experiences with complementary therapies may have 
added to this effect. Furthermore even the sham procedure included some minor stimulation in the beginning, 
when the cups were placed on the back, and the air was evacuated from the cups. Therefore the sham may be 
considered a minimal cupping, and exert effects similar to those that have been observed in trials using sham 
acupuncture for low back pain50,51.
Strengths and limitations. The strengths of the study include the randomised study design; the use of two 
different comparators; and the blinding of patients in the active treatment groups as well as outcome assessors. 
Outcomes were further chosen according to the guiding symptoms of fibromyalgia according to current defini-
tions4,52; however only pain was selected as the primary outcome because it was considered the most important 
outcome. The low number of drop-outs at the post-intervention measurement and the overall good compliance 
also indicated that the tested interventions were tolerable. Finally analgesic medication and concomitant treat-
ments were evaluated and their influence on the outcomes ruled out.
Limitations include the non-successful blinding of patients, however due to the positive connotation of the 
seemingly gentle cupping the placebo effect was preserved. Patients in the study were mainly female in their mid-
40 and 50’s, limiting the significance of the trial’s findings for male, younger and older patients with fibromyalgia. 
Figure 2. Results from the daily log, (a) pain intensity; (b) analgesic medication use and (c) use of concomitant 
therapies during the trial period, Mean and SD/SE. Please note: Each time point reflects an average of 3–4 days 
(C1: average of scores from the day of cupping #1 and the days until cupping #2; C2: average of scores from the 
day of cupping #2 and the days until cupping #3; and so forth). Averages were calculated according to individual 
treatment time plan. SD/SE are presented as positive or negative bars only to increase visibility.
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It is known that the vast majority of fibromyalgia patients are female with only 1 in 10 patients being male2. The 
inclusion of two male patients only might be related to different factors, including the female patients’ preference 
towards complementary and alternative medicine, however similarly low rates of males have been found in many 
other studies including CAM53, pharmacotherapy54 studies or psychotherapy55. Further studies should examine 
the barriers for male fibromyalgia patients to participate in clinical trials, and ensure that more male patients are 
approached directly to increase a balanced sample.
Future studies. More studies are warranted to evaluate the effects of different cupping techniques of different 
durations on chronic pain syndromes. For fibromyalgia in particular the effects in patients with certain subtypes 
should be determined. It may also be interesting to test cupping as part of a multimodal treatment approach, or 
in combination with therapies like acupuncture. Further studies should also re-evaluate the sham cupping device 
and – if necessary – develop reliable alternatives.
Conclusion
Five cupping treatments were more effective than usual care to improve pain intensity and quality of life in 
patients diagnosed with the fibromyalgia syndrome. Given that effects were small, and cupping was not superior 
to sham cupping treatments currently no recommendation for cupping in the treatment of fibromyalgia can be 
made. Further research is warranted for conclusive judgement of the efficacy of cupping therapy for chronic pain.
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